Abstract: A shaving implement comprises a cutting portion and an end portion. Further, the cutting portion transitions between a straight configuration and a bent configuration based on an application of an external force on the cutting portion. forming a bend in the cutting portion characterized by a curvature and a direction. Further, transitioning the cutting portion from the configuration to the straight configuration comprises removing the bend. Further, the cutting portion is not transitionable between the straight configuration and the bent configuration without the application of the external force. Further, the cutting portion comprises a blade slot for receiving a blade. Further, the cutting portion curves the blade in a blade shape based on the forming of the bend. Further, the end portion removably holds the cutting portion.

Abstract: A shaving implement comprises a cutting portion and an end portion. Further, the cutting portion transitions between a straight configuration and a bent configuration based on an application of an external force on the cutting portion. forming a bend in the cutting portion characterized by a curvature and a direction. Further, transitioning the cutting portion from the configuration to the straight configuration comprises removing the bend. Further, the cutting portion is not transitionable between the straight configuration and the bent configuration without the application of the external force. Further, the cutting portion comprises a blade slot for receiving a blade. Further, the cutting portion curves the blade in a blade shape based on the forming of the bend. Further, the end portion removably holds the cutting portion.

Abstract: The invention generally provides compositions and methods of treating or preventing an arenavirus infection, using an agent that inhibits binding of an arenavirus glycoprotein 1 (GP1) polypeptide to transferrin receptor 1 (TfR1). The invention also provides methods of designing or identifying therapeutic agents that bind to or target a GP1 receptor-binding site (RBS) to inhibit arenavirus attachment to a cell, and therapeutic agents identified using the methods.

Abstract: The invention generally provides compositions and methods of treating or preventing an arenavirus infection, using an agent that inhibits binding of an arenavirus glycoprotein 1 (GP1) polypeptide to transferrin receptor 1 (TfR1). The invention also provides methods of designing or identifying therapeutic agents that bind to or target a GP1 receptor-binding site (RBS) to inhibit arenavirus attachment to a cell, and therapeutic agents identified using the methods.